We have previously reported that a human small cell lung cancer (SCLC) cell line (COR L103) 
small cell lung cancer Cushing's syndrome continues to pose difficulties in diagnosis and management despite the advent in recent years of corticotropin-releasing factor (CRF)' testing and sophisticated venous sampling and imaging techniques. Many ofthese difficulties center around the ectopic ACTH syndrome, in which ACTH is secreted by an extrapituitary tumor. Characteristically, POMC gene expression and ACTH secretion is unaltered by glucocorticoids, in contrast to corticotroph adenomas ofthe pituitary (1) . In addition, limited processing of POMC results in the secretion of high molecular weight precursor forms of ACTH (2) . We have recently described a human small cell lung cancer (SCLC) cell line which secretes POMC and pro-ACTH (3, 4) and is resistant to glucocorticoid regulation of POMC gene expression and peptide secretion, thus mimicking the in vivo findings (4) and behaving as a model of human ectopic ACTH production.
In the normal pituitary, CRF stimulates cAMP accumulation, which in turn results in increased POMC gene expression and peptide secretion. Resistance to CRF in ectopic ACTH secreting tumors is generally assumed to be due to the absence of CRF receptors, although there is no evidence as to whether the adenyl cyclase/cAMP signaling system is intact. It is possible that stimulation ofthis system by other receptors that modulate cAMP could provide new diagnostic tests for the condition. In addition, inhibition of the system by other agents that act through cyclase inhibitory receptors could provide alternative therapeutic options.
We have therefore tested the response of POMC gene expression and peptide secretion to cAMP in SCLC cell lines. As we will show, cAMP remains an effective stimulus of POMC gene expression, and thus we have investigated whether one agent, the dopamine agonist bromocriptine, which acts primarily through D2 receptors to inhibit cAMP production is an effective suppressor of POMC.
Methods
This work was presented in part at the 73rd Annual Meeting of the American Endocrine Society, June 199 1, and was published in abstract form at that meeting (Abstr. 877).
atmosphere of 5% CO2. The relatively long doubling times ofthese cell lines ( -4 d) in culture and their growth as floating aggregates limited the number ofcultures that could be used in some experiments. AtT20 cells were cultured as described (S) in Ham's FlO medium (Flow Laboratories, Inc., McLean, VA) supplemented with horse serum (15%), fetal calfserum (2.5%), and glutamine (4 mM) in an atmosphere of5% CO2 at 37°C.
Experimental design. Cells were grown to stationary phase and then passaged in one quarter vol fresh medium to generate three flasks of cells, all at the same cell density and stage ofgrowth. Bromocriptine (Sandoz, AG, Basel, Switzerland), phenoxybenzamine (Smith Kline & French Laboratories, Philadelphia, PA) and db cAMP (Sigma Chemical Co., St. Louis, MO) were initially prepared as concentrated stock solutions in DMSO, such that the concentration of solvent did not exceed 0.1% in test cultures. Controls received an equal volume of vehicle alone. All incubations were performed in triplicate. For the second messenger studies, cell pellets from each time point were combined for RNA extraction because of the limitations imposed by slow cell growth. Harvesting of cells at the end of the experiment involved assessment of cell viability by trypan blue exclusion, removal of a 0.5-ml sample of the cell suspension for protein analysis and pelleting of the cells which were then flash frozen and stored at -70°C for RNA preparation. The culture medium was frozen and retained for measurement of ACTH precursor peptides and estradiol.
Studies ofwithdrawal ofbromocriptine challenge. Culture medium was removed and flash frozen 24 h after challenge with bromocriptine ( 15 M1M). Cells were washed extensively in PBS three times and recultured in the same volume offresh culture medium and sampled 24 and 48 h later. Longer term studies were essentially the same except that cells were seeded at one quarter the density post challenge and washing.
Immunoradiometric assay for precursor peptides. The development of the precursor assay is described in detail elsewhere (6) . mAb lA12 (specific for ACTH 10-18) was radioiodinated, and mAb lCl 1 (specific for gamma-MSH) was coupled to Sephacryl S300 as solid phase. Binding of both antibodies is required to generate a signal. The POMC standard was prepared from growth medium of a cultured human pituitary tumor by purification of the peptides using Sephadex G-75 chromatography under acid dissociating conditions. Standards were prepared at concentrations of0-2600 pmol/liter. The assay sensitivity is 2.6 pmol/liter, and the within and between assay CVs are < 10% between 20-2,600 pmol/liter and 37-2,600 pmol/liter, respectively. The Quantitative RNA analysis. 5-Ag aliquots ofeach RNA sample were applied to nylon backed nitrocellulose filters (Hybond C Extra; Amersham International) using a slot blot apparatus (Gibco BRL Grand Island, NY). Blots were hybridized at moderately high stringency (50% formamide at 42°C) to the DNA probes described below. After hybridization for 16 h, the filters were washed 5 times at 42°C in 2 x standard saline citrate (SSC).
( 1 x SSC is 0.15 M sodium chloride, 0.015 M sodium citrate), 0.1% SDS and then twice in 0.2 x SSC, 0.1% SDS, and finally twice at high stringency 0.1 x SSC, 0.1% SDS at 42°C. Autoradiography was carried out at -70°C with image intensifying screens and Kodak XAR-5 film, for intervals ranging from 1 to 5 d in order to obtain a suitably contrasted image with each ofthe probes used. Autoradiographs were quantitated with a dual wavelength densitometer (CS 9,000; Shimadzu Corp., Kyoto, Japan), and all results are expressed relative to the ,B-actin mRNA as a control for the quality and quantity of RNA applied to the blot.
Northern blot analysis. Total cellular RNA was separatedby electrophoresis (2 V/cm for 15 h) on 1.4% (wt/vol) agarose/formaldehyde (6.5% vol/vol) gels run in 20 mM 3-(N-morpholino) propanesulphonic acid (MOPS) buffer (pH 7). RNA samples were denatured before loading by heating to 650C in 33% formamide/5% formaldehyde/20 mM MOPS, cooling on ice and adding glycerol and dyes. After electrophoresis, gels were stained with ethidium bromide (5 ,ug/ ml), destained to visualise the 18S and 28S RNA bands and then transferred to nylon backed nitrocellulose paper (Hybond C extra) in 20 x SSC. The membrane was baked in a vacuum oven (80°C for 2 h) and prehybridized and hybridized as described previously (8) . Posthybridization blots were washed under high stringency as described for slot blot analysis. Probes. The probe used was an 800-bp insert derived from exon 3 of the cloned human POMC gene (9). The 13-actin probe was derived from the cloned chick beta actin cDNA. All probes were labeled using the oligoprimed labeling technique (10) and were purified by passage over Sephadex G-50. Specific activity was usually I09 cpm/,Mg, and all of the labeled probe was used in the hybridization reaction. Statistical analysis. Results were analyzed by the Student's unpaired t test. Dose response curves were assessed by regression analysis. In some experiments (response to db cAMP) the yield of POMC RNA was low, necessitating pooling of samples from triplicate experiments. In these studies, statistical analysis was therefore not possible.
Results
Effect ofdb-cAMP. Incubation of the COR L24 cell line with db cAMP ( 10-3 M) for 0.5 to 48 h demonstrated a significant increase in ACTH precursor peptides at 24 and 48 h (-1.5-and twofold higher, respectively). POMC mRNA levels were higher in the db-cAMP treated cells than in the controls at 5, 24, and 48 h ( 1.5-, 3-, 4-fold increase, respectively), (Fig. 1) .
Effects of bromocriptine on ACTH precursors. COR L24 cells secrete significant levels ofACTH precursor peptides, as it has been previously described (3, 4) , with relatively small amounts of ACTH 1-39. COR L24 cells were incubated with 0.15-15 MM bromocriptine for 24 h and ACTH precursor peptide levels were reduced in a dose-dependent manner (Fig. 2 (Fig. 3 A) . in response to bromocriptine (Fig. 3 C) , suggesting a specific effect of bromocriptine on ACTH precursors in the SCLC cell line. No inhibition of peptides was evident in the AtT20 cell line (in which POMC is not under dopaminergic control) at 15 MM bromocriptine confirming that this compound had no effect on corticotroph adenoma cells (Fig. 3 B) . Effect ofwithdrawal ofbromocriptine challenge. Inhibition of ACTH precursors in the 48 h postchallenge was essentially unchanged (Fig. 4 B) from that seen in the initial 24 h when the drug was present (Fig. 4 A) . Further washing and reculture in fresh media ( in an autocrine loop in SCLC ( 13) . In addition, POMC expression could also adversely effect the morbidity and mortality associated with this tumor by means of ACTH stimulation of the adrenal cortex. Thus 50% of patients with SCLC have been found to have elevated cortisol levels ( 14) and 2.5-7% have clinically detectable features of the ectopic ACTH syndrome ( 15) . Furthermore, POMC expressing SCLC acts as a model for the ectopic ACTH syndrome resulting from pulmonary tumors. This syndrome remains one of the most clinically trying endocrine conditions, and therefore a significant contribution to the management of these conditions could be made if a means of controlling POMC gene expression were found. Such an understanding is obviously difficult in patients with SCLC with or without features of glucocorticoid excess, since they are often severely ill on presentation, and therapeutic intervention to treat the tumor cannot be delayed. Several groups have used an approach based on SCLC cell lines in order to try to understand the oncological problems of these tumors. We have used this approach to try to understand some ofthe endocrine problems ofSCLC and have described a SCLC cell line as a model of the ectopic ACTH-secreting tumor, showing that it secretes predominantly POMC precursor peptides (3) and is resistant to glucocorticoid regulation (4), thus mimicking the in vivo situation.
We now report our finding that POMC in these cells is under the positive regulation of cAMP. This is consistent with the regulation of this gene in the corticotroph cells of the anterior pituitary, where the principal stimulator of adenyl cyclase is CRF ( 16 Subsequently, we have sought some means ofinhibiting the cAMP signal in these tumors, and have examined the possibility that dopaminergic stimulation through D2 receptors which are linked to Gi might achieve this end. We have shown that the D2 agonist bromocriptine, inhibited cAMP production and suppressed ACTH precursor peptide levels in a dose dependent manner without appearing to have any effect on cell viability both in a 24-h and 7-d incubation (data not shown). Multiple hormone secretion by established SCLC cell lines has been reported previously ( 18) and in these studies the majority of cell lines secrete estradiol. We have exploited this property to compare the effect of bromocriptine on the secretion of ACTH precursors and estradiol. This enabled us to show that bromocriptine specifically suppressed ACTH precursors while estradiol was unaffected. In support of these findings, bromocriptine failed to suppress ACTH precursor peptides in the AtT20 cell line, confirming that there is differential regulation of POMC in corticotroph adenoma cells and SCLC cells. In response to bromocriptine, POMC mRNA was also suppressed whereas no suppression oftranscript expression was seen in the AtT20 cell line. Suppression ofPOMC gene expression relative to the "housekeeping" gene 3-actin further demonstrates that the effects of bromocriptine are specific and not a general down-regulation of transcriptional and translational mechanisms.
Removal of the bromocriptine challenge from the SCLC cells did not result in a recovery of ACTH precursor peptide secretion in the initial 48 h after washing and incubating cells in fresh medium. When cells were seeded at a lower density postchallenge, peptide output could be monitored over a longer time course. Accumulated peptides detected between day 3 and day 8 increased in parallel with control cultures. In addition, no significant difference in cell number was detected in the 4 d postchallenge between control and treated cells with a doubling time of -3.5 d. In our view, the most probable explanation for this prolonged effect of bromocriptine is the low transcriptional rate of the POMC gene in these cells. Circumstantial evidence from other studies with these cells suggests that the POMC mRNA is unusually stable and the db-cAMP studies reported here show that significant changes in POMC mRNA are only apparent after 24 h, even though the transcriptional effect ofthis second messenger is probably accomplished within a few hours ofapplication. Thus, it seems likely that this mRNA has a low rate of turnover, and this explains our inability to see recovery of mRNA levels within 48 h of bromocriptine withdrawal in the absence of some positive stimulus. A specific effect on POMC mRNA stability cannot be overruled and has been reported to occur in the rat intermediate lobe ( 19) . Bromocriptine was selected for these studies because it is primarily a D2 agonist that has been used extensively in vivo. It is unlikely that this action is mediated through its well characterized a-adrenoceptor antagonism (20) , since incubation with the a-adrenoceptor antagonist, phenoxybenzamine, did not suppress peptide levels. (23) have shown that argyrophilic fibers can be identified not only in corticotroph adenomas adjacent to the posterior lobe, but also in tumors situated deep in the anterior lobe. In vivo suppression of ACTH in response to bromocriptine in one patient with a nonpituitary tumor (lung carcinoid) has been reported previously (24) . To our knowledge, with this exception, few studies have addressed the regulation of ACTH and related peptides in nonpituitary tumors. We have approached this problem using an in vitro model of the ectopic ACTH syndrome and find that bromocriptine specifically inhibits POMC gene expression and peptide secretion. In vivo, the effects of bromocriptine and other ergot derivatives on the regulation of cortisol excess and tumor progression should be readily testable. In addition, this drug may prove to have a role in the differential diagnosis of pituitary versus ectopic tumors.
